Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan

Arcturus Therapeutics Holdings Inc.

Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.
Phase III trial of ARCT-154 started Dec 12, 2022, targeting 780 participants; enrollment completed with 828 in Feb 2023.
Arcturus has a Collaboration and License Agreement with CSL Seqirus since Dec 8, 2022 for global rights to self-amplifying mRNA vaccines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.